Marc Ferrante Selected Research

Interleukin-23 (Interleukin 23)

1/2022	Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
12/2021	Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.
1/2020	Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
10/2018	Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
7/2017	A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.
1/2017	Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marc Ferrante Research Topics

Disease

80	Crohn Disease (Crohn's Disease) 03/2024 - 12/2005
73	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 04/2024 - 09/2006
72	Ulcerative Colitis 05/2024 - 06/2006
24	Necrosis 04/2024 - 09/2011
24	Inflammation (Inflammations) 11/2023 - 09/2006
12	Colitis 10/2021 - 02/2007
11	Neoplasms (Cancer) 01/2023 - 02/2014
8	Pouchitis 05/2024 - 01/2008
8	Infections 01/2022 - 02/2014
6	Abdominal Pain (Pain, Abdominal) 10/2023 - 12/2013
5	Fistula 11/2022 - 02/2010
5	Fibrosis (Cirrhosis) 01/2020 - 09/2008
4	Dysbiosis 12/2023 - 08/2014
4	Hemorrhage 08/2023 - 01/2020
4	Disease Progression 12/2020 - 10/2013
3	Fatigue 08/2023 - 05/2022
3	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 01/2016
2	Rheumatoid Arthritis 01/2022 - 02/2014
2	Cystic Fibrosis (Mucoviscidosis) 11/2021 - 01/2021
2	Body Weight (Weight, Body) 01/2021 - 09/2019
2	Ulcer 12/2018 - 01/2014
2	Ileitis 10/2018 - 06/2008
2	Iron Deficiencies 01/2017 - 12/2007
1	Obesity 12/2023
1	Proctitis 07/2023
1	Nasopharyngitis 02/2023
1	Headache (Headaches) 02/2023
1	Exanthema (Rash) 02/2023
1	Acne Vulgaris 02/2023
1	Microsatellite Instability 01/2023
1	COVID-19 01/2023
1	Turcot syndrome 01/2023

Drug/Important Bio-Agent (IBA)

44	Infliximab (Remicade)FDA Link 03/2024 - 03/2006
24	vedolizumabIBA 03/2024 - 09/2017
16	Biomarkers (Surrogate Marker)IBA 04/2024 - 12/2012
15	Adalimumab (Humira)FDA Link 10/2023 - 11/2009
15	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2021 - 09/2008
14	AntibodiesIBA 12/2021 - 10/2007
9	Monoclonal AntibodiesIBA 12/2021 - 09/2008
8	Ustekinumab (CNTO 1275)FDA Link 05/2024 - 07/2017
8	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2023 - 02/2007
8	SteroidsIBA 01/2022 - 06/2006
8	Immunologic Factors (Immunomodulators)IBA 10/2021 - 10/2013
7	risankizumabIBA 01/2024 - 01/2017
7	golimumab FDA Link 01/2022 - 05/2016
7	Dextrans (Dextran)FDA Link 12/2020 - 01/2013
6	Interleukin-23 (Interleukin 23)IBA 01/2022 - 01/2017
5	SodiumIBA 12/2020 - 01/2013
5	CytokinesIBA 11/2019 - 01/2013
4	IntegrinsIBA 11/2023 - 04/2018
4	C-Reactive ProteinIBA 11/2023 - 01/2018
4	tofacitinibIBA 08/2023 - 05/2018
4	Proteins (Proteins, Gene)FDA Link 01/2023 - 02/2014
4	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 02/2010
4	Biosimilar PharmaceuticalsIBA 06/2020 - 01/2017
4	Tumor Necrosis Factor InhibitorsIBA 04/2018 - 01/2014
4	Phenobarbital (Luminal)FDA Link 02/2010 - 03/2006
3	Leukocyte L1 Antigen Complex (Calgranulin)IBA 11/2023 - 12/2012
3	InterleukinsIBA 02/2023 - 01/2019
3	EnzymesIBA 11/2022 - 07/2014
3	CT-P13IBA 08/2022 - 01/2019
3	Janus Kinase InhibitorsIBA 01/2022 - 05/2018
3	Interleukin-12 (IL 12)IBA 07/2019 - 05/2018
3	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2017 - 07/2014
3	Matrix Metalloproteinases (MMPs)IBA 01/2017 - 02/2014
3	PorinsIBA 06/2008 - 10/2007
2	Volatile Fatty AcidsIBA 12/2023 - 01/2023
2	Budesonide (Pulmicort)FDA LinkGeneric 11/2023 - 03/2019
2	mirikizumabIBA 01/2022 - 01/2020
2	ChloridesIBA 11/2021 - 10/2006
2	2-mercaptopurineIBA 01/2021 - 01/2020
2	AntigensIBA 09/2020 - 11/2007
2	Drinking WaterIBA 01/2020 - 01/2018
2	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2020 - 01/2018
2	Hydroxyproline (4 Hydroxyproline)IBA 01/2020 - 11/2019
2	Interleukin-17 (Interleukin 17)IBA 11/2019 - 05/2018
2	Butyrates (Butyrate)IBA 09/2019 - 08/2014
2	MicroRNAs (MicroRNA)IBA 07/2019 - 01/2014
2	Azathioprine (Imuran)FDA LinkGeneric 03/2019 - 08/2015
2	Methotrexate (Mexate)FDA LinkGeneric 03/2019 - 01/2019
2	Immunoglobulin G (IgG)IBA 01/2019 - 11/2007
2	Messenger RNA (mRNA)IBA 01/2018 - 01/2014
2	IronIBA 01/2017 - 12/2007
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2017 - 06/2006
2	Peptides (Polypeptides)IBA 01/2017 - 10/2007
2	Ferritins (Ferritin)IBA 01/2017 - 11/2005
2	ImmunosorbentsIBA 05/2016 - 07/2014
2	LipocalinsIBA 12/2015 - 07/2014
2	Pattern Recognition ReceptorsIBA 06/2008 - 11/2007
2	EpitopesIBA 11/2007 - 10/2007
2	Tranexamic Acid (AMCA)FDA Link 11/2007 - 10/2007
1	Histone Deacetylase InhibitorsIBA 12/2023
1	Ciprofloxacin (Cipro)FDA LinkGeneric 03/2023
1	spesolimabIBA 02/2023
1	GLPG0634IBA 01/2023
1	Immunomodulating AgentsIBA 01/2023

Therapy/Procedure

76	Therapeutics 04/2024 - 11/2005
16	Biological Therapy 12/2023 - 12/2009
11	Restorative Proctocolectomy 05/2024 - 01/2008
7	Colectomy 10/2017 - 06/2006